--- title: "EXAS.US (EXAS.US) — Related News" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/EXAS.US/news.md" symbol: "EXAS.US" name: "EXAS.US" parent: "https://longbridge.com/en/quote/EXAS.US.md" datetime: "2026-05-20T12:46:29.336Z" locales: - [en](https://longbridge.com/en/quote/EXAS.US/news.md) - [zh-CN](https://longbridge.com/zh-CN/quote/EXAS.US/news.md) - [zh-HK](https://longbridge.com/zh-HK/quote/EXAS.US/news.md) --- # EXAS.US (EXAS.US) — Related News ### [Exact Sciences Deal and Legal Pressures Might Change The Case For Investing In Abbott (ABT)](https://longbridge.com/en/news/286516235.md) *2026-05-15T06:10:55.000Z* > Abbott Laboratories recently completed a $21 billion acquisition of Exact Sciences, aiming to enhance its cancer diagnos ### [Abbott Laboratories' dividend yield is approaching a ten-year high, presenting a rare buying opportunity](https://longbridge.com/en/news/286138168.md) *2026-05-12T17:35:32.000Z* > Abbott Laboratories' dividend yield is nearing a ten-year high, reflecting the dual pressure on its stock price from the ### [Abbott Laboratories Analysts Slash Their Forecasts After Q1 Earnings](https://longbridge.com/en/news/283154648.md) *2026-04-17T13:21:29.000Z* > Abbott Laboratories (NYSE:ABT) reported strong Q1 earnings but lowered its 2026 outlook, citing dilution from the Exact ### [Key facts: Abbott Q1 diagnostics -7.4%; guidance cut; Exact Sciences](https://longbridge.com/en/news/283048446.md) *2026-04-16T20:07:25.000Z* > Abbott (ABT) Q1 sales fell; rapid and molecular diagnostics down 7.4% to $812M, weaker nutrition and diabetes device sal ### [Abbott lowers profit expectations after completing a $21 billion deal, reflecting the impact of the $21 billion acquisition](https://longbridge.com/en/news/283044721.md) *2026-04-16T19:20:37.000Z* > Abbott Laboratories (ABT) lowered its full-year earnings forecast after completing the $21 billion acquisition of Exact ### [Abbott Laboratories Stock (ABT) Opened Down by 4.34% on Apr 16: What Investors Need To Know](https://longbridge.com/en/news/283013884.md) *2026-04-16T13:51:18.000Z* > Abbott Laboratories (ABT) opened down 4.34% amid a 3.44% decline in the Healthcare Services & Equipment sector. The drop ### [Abbott Updates FY26 Guidance To Reflect Acquisition Of Exact Sciences](https://longbridge.com/en/news/282997106.md) *2026-04-16T12:10:30.000Z* > Abbott (ABT) has updated its FY26 guidance, projecting adjusted EPS of $5.38 to $5.58, factoring in a $0.20 dilution fro ### [Abbott reports Q1 2026: Revenue $11.16B, adjusted diluted EPS $1.15; updates 2026 guidance](https://longbridge.com/en/news/282992899.md) *2026-04-16T11:43:00.000Z* > Abbott reported Q1 2026 results with revenue of $11.16 billion and adjusted diluted EPS of $1.15, a 6% increase year-ove